LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 12

Search options

  1. Article ; Online: Upper limb movements as digital biomarkers in people with ALS.

    Straczkiewicz, Marcin / Karas, Marta / Johnson, Stephen A / Burke, Katherine M / Scheier, Zoe / Royse, Tim B / Calcagno, Narghes / Clark, Alison / Iyer, Amrita / Berry, James D / Onnela, Jukka-Pekka

    EBioMedicine

    2024  Volume 101, Page(s) 105036

    Abstract: Background: Objective evaluation of people with amyotrophic lateral sclerosis (PALS) in free-living settings is challenging. The introduction of portable digital devices, such as wearables and smartphones, may improve quantifying disease progression and ...

    Abstract Background: Objective evaluation of people with amyotrophic lateral sclerosis (PALS) in free-living settings is challenging. The introduction of portable digital devices, such as wearables and smartphones, may improve quantifying disease progression and hasten therapeutic development. However, there is a need for tools to characterize upper limb movements in neurologic disease and disability.
    Methods: Twenty PALS wore a wearable accelerometer, ActiGraph Insight Watch, on their wrist for six months. They also used Beiwe, a smartphone application that collected self-entry ALS Functional Rating Scale-Revised (ALSFRS-RSE) survey responses every 1-4 weeks. We developed several measures that quantify count and duration of upper limb movements: flexion, extension, supination, and pronation. New measures were compared against ALSFRS-RSE total score (Q1-12), and individual responses to specific questions related to handwriting (Q4), cutting food (Q5), dressing and performing hygiene (Q6), and turning in bed and adjusting bed clothes (Q7). Additional analysis considered adjusting for total activity counts (TAC).
    Findings: At baseline, PALS with higher Q1-12 performed more upper limb movements, and these movements were faster compared to individuals with more advanced disease. Most upper limb movement metrics had statistically significant change over time, indicating declining function either by decreasing count metrics or by increasing duration metric. All count and duration metrics were significantly associated with Q1-12, flexion and extension counts were significantly associated with Q6 and Q7, supination and pronation counts were also associated with Q4. All duration metrics were associated with Q6 and Q7. All duration metrics retained their statistical significance after adjusting for TAC.
    Interpretation: Wearable accelerometer data can be used to generate digital biomarkers on upper limb movements and facilitate patient monitoring in free-living environments. The presented method offers interpretable monitoring of patients' functioning and versatile tracking of disease progression in the limb of interest.
    Funding: Mitsubishi-Tanabe Pharma Holdings America, Inc.
    MeSH term(s) Humans ; Amyotrophic Lateral Sclerosis/diagnosis ; Upper Extremity ; Wrist ; Disease Progression ; Biomarkers
    Chemical Substances Biomarkers
    Language English
    Publishing date 2024-03-02
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2851331-9
    ISSN 2352-3964
    ISSN (online) 2352-3964
    DOI 10.1016/j.ebiom.2024.105036
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Longitudinal comparison of the self-administered ALSFRS-RSE and ALSFRS-R as functional outcome measures in ALS.

    Erb, M Kelley / Calcagno, Narghes / Brown, Roland / Burke, Katherine M / Scheier, Zoe A / Iyer, Amrita S / Clark, Alison / Higgins, Max P / Keegan, Mackenzie / Gupta, Anoopum S / Johnson, Stephen A / Chew, Sheena / Berry, James D

    Amyotrophic lateral sclerosis & frontotemporal degeneration

    2024  , Page(s) 1–11

    Abstract: ... ...

    Abstract Objective
    Language English
    Publishing date 2024-03-19
    Publishing country England
    Document type Journal Article
    ZDB-ID 2705049-X
    ISSN 2167-9223 ; 2167-8421
    ISSN (online) 2167-9223
    ISSN 2167-8421
    DOI 10.1080/21678421.2024.2322549
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Longitudinal comparison of the self-entry Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-RSE) and Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) as outcome measures in people with amyotrophic lateral sclerosis.

    Johnson, Stephen A / Burke, Katherine M / Scheier, Zoe A / Keegan, Mackenzie A / Clark, Alison P / Chan, James / Fournier, Christina N / Berry, James D

    Muscle & nerve

    2022  Volume 66, Issue 4, Page(s) 495–502

    Abstract: Introduction/aims: Improved functional outcome measures in amyotrophic lateral sclerosis (ALS) would aid ALS trial design and help hasten drug discovery. We evaluate the longitudinal performance of the Rasch-Built Overall Amyotrophic Lateral Sclerosis ... ...

    Abstract Introduction/aims: Improved functional outcome measures in amyotrophic lateral sclerosis (ALS) would aid ALS trial design and help hasten drug discovery. We evaluate the longitudinal performance of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) compared to the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised for Self-Entry (ALSFRS-RSE) as patient reported outcomes of functional status in people with ALS.
    Methods: Participants completed the ROADS and the ALSFRS-RSE questionnaires at baseline, 3-, 6-, and 12- mo using Research Electronic Data Capture as part of a prospective, longitudinal, remote, online survey study of fatigue in ALS from 9/2020 to 12/2021. The scales were compared cross-sectionally (at baseline) and longitudinally. Correlation coefficients, coefficients of variation, and descriptive statistics were assessed.
    Results: A total of 182 adults with ALS consented to the study. This volunteer sample was comprised of predominantly White, non-Hispanic, non-smoking participants. Consented participant survey completion was approximately 90% at baseline and greater than 40% at 12 mo. The ALSFRS-RSE and the ROADS had high, significant agreement at 3 and 6 mo by Cohen's kappa ≥71% (p < 0.001); the number of functional increases or plateaus on the two scales were not significantly different; and the coefficient of variation of functional decline was similar at the 6-month mark, though higher for the ROADS at 3 mo and lower at 12 mo.
    Discussion: Although the ROADS performed similarly to the ALSFRS-RSE in an observational cohort, it has psychometric advantages, such as Rasch-modeling and unidimensionality. It merits further investigation as a patient reported outcome of overall disability and efficacy outcome measure in ALS trials.
    MeSH term(s) Adult ; Amyotrophic Lateral Sclerosis/diagnosis ; Disabled Persons ; Disease Progression ; Humans ; Outcome Assessment, Health Care ; Prospective Studies ; Surveys and Questionnaires
    Language English
    Publishing date 2022-08-15
    Publishing country United States
    Document type Journal Article ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 438353-9
    ISSN 1097-4598 ; 0148-639X
    ISSN (online) 1097-4598
    ISSN 0148-639X
    DOI 10.1002/mus.27691
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Wearable device and smartphone data quantify ALS progression and may provide novel outcome measures.

    Johnson, Stephen A / Karas, Marta / Burke, Katherine M / Straczkiewicz, Marcin / Scheier, Zoe A / Clark, Alison P / Iwasaki, Satoshi / Lahav, Amir / Iyer, Amrita S / Onnela, Jukka-Pekka / Berry, James D

    NPJ digital medicine

    2023  Volume 6, Issue 1, Page(s) 34

    Abstract: Amyotrophic lateral sclerosis (ALS) therapeutic development has largely relied on staff-administered functional rating scales to determine treatment efficacy. We sought to determine if mobile applications (apps) and wearable devices can be used to ... ...

    Abstract Amyotrophic lateral sclerosis (ALS) therapeutic development has largely relied on staff-administered functional rating scales to determine treatment efficacy. We sought to determine if mobile applications (apps) and wearable devices can be used to quantify ALS disease progression through active (surveys) and passive (sensors) data collection. Forty ambulatory adults with ALS were followed for 6-months. The Beiwe app was used to administer the self-entry ALS functional rating scale-revised (ALSFRS-RSE) and the Rasch Overall ALS Disability Scale (ROADS) surveys every 2-4 weeks. Each participant used a wrist-worn activity monitor (ActiGraph Insight Watch) or an ankle-worn activity monitor (Modus StepWatch) continuously. Wearable device wear and app survey compliance were adequate. ALSFRS-R highly correlated with ALSFRS-RSE. Several wearable data daily physical activity measures demonstrated statistically significant change over time and associations with ALSFRS-RSE and ROADS. Active and passive digital data collection hold promise for novel ALS trial outcome measure development.
    Language English
    Publishing date 2023-03-06
    Publishing country England
    Document type Journal Article
    ISSN 2398-6352
    ISSN (online) 2398-6352
    DOI 10.1038/s41746-023-00778-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Ultrasound-guided glenohumeral joint injections for shoulder pain in ALS: A case series.

    Burke, Katherine M / Ellrodt, Amy S / Joslin, Benjamin C / Sanpitak, Pia P / MacAdam, Claire / Deo, Prabhav / Ozment, Kevin / Shea, Cristina / Johnson, Stephen A / Ho, Doreen / Chu, Samuel K / Babu, Ashwin N / Franz, Colin K / Paganoni, Sabrina

    Frontiers in neurology

    2023  Volume 13, Page(s) 1067418

    Abstract: Introduction: Shoulder pain is a common secondary impairment for people living with ALS (PALS). Decreased range of motion (ROM) from weakness can lead to shoulder pathology, which can result in debilitating pain. Shoulder pain may limit PALS from ... ...

    Abstract Introduction: Shoulder pain is a common secondary impairment for people living with ALS (PALS). Decreased range of motion (ROM) from weakness can lead to shoulder pathology, which can result in debilitating pain. Shoulder pain may limit PALS from participating in activities of daily living and may have a negative impact on their quality of life. This case series explores the efficacy of glenohumeral joint injections for the management of shoulder pain due to adhesive capsulitis in PALS.
    Methods: People living with ALS and shoulder pain were referred to sports medicine-certified physiatrists for diagnostic evaluation and management. They completed the Revised ALS Functional Rating Scale and a questionnaire asking about their pain levels and how it impacts sleep, function, and quality of life at baseline pre-injection, 1-week post-injection, 1 month post-injection, and 3 months post-injection.
    Results: We present five cases of PALS who were diagnosed with adhesive capsulitis and underwent glenohumeral joint injections. Though only one PALS reported complete symptom resolution, all had at least partial symptomatic improvement during the observation period. No complications were observed.
    Conclusions: People living with ALS require a comprehensive plan to manage shoulder pain. Glenohumeral joint injections are safe and effective for adhesive capsulitis in PALS, but alone may not completely resolve shoulder pain. Additional therapies to improve ROM and reduce pain should be considered.
    Language English
    Publishing date 2023-02-02
    Publishing country Switzerland
    Document type Case Reports
    ZDB-ID 2564214-5
    ISSN 1664-2295
    ISSN 1664-2295
    DOI 10.3389/fneur.2022.1067418
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Using Smartphones to Reduce Research Burden in a Neurodegenerative Population and Assessing Participant Adherence: A Randomized Clinical Trial and Two Observational Studies.

    Beukenhorst, Anna L / Burke, Katherine M / Scheier, Zoe / Miller, Timothy M / Paganoni, Sabrina / Keegan, Mackenzie / Collins, Ella / Connaghan, Kathryn P / Tay, Anna / Chan, James / Berry, James D / Onnela, Jukka-Pekka

    JMIR mHealth and uHealth

    2022  Volume 10, Issue 2, Page(s) e31877

    Abstract: Background: Smartphone studies provide an opportunity to collect frequent data at a low burden on participants. Therefore, smartphones may enable data collection from people with progressive neurodegenerative diseases such as amyotrophic lateral ... ...

    Abstract Background: Smartphone studies provide an opportunity to collect frequent data at a low burden on participants. Therefore, smartphones may enable data collection from people with progressive neurodegenerative diseases such as amyotrophic lateral sclerosis at high frequencies for a long duration. However, the progressive decline in patients' cognitive and functional abilities could also hamper the feasibility of collecting patient-reported outcomes, audio recordings, and location data in the long term.
    Objective: The aim of this study is to investigate the completeness of survey data, audio recordings, and passively collected location data from 3 smartphone-based studies of people with amyotrophic lateral sclerosis.
    Methods: We analyzed data completeness in three studies: 2 observational cohort studies (study 1: N=22; duration=12 weeks and study 2: N=49; duration=52 weeks) and 1 clinical trial (study 3: N=49; duration=20 weeks). In these studies, participants were asked to complete weekly surveys; weekly audio recordings; and in the background, the app collected sensor data, including location data. For each of the three studies and each of the three data streams, we estimated time-to-discontinuation using the Kaplan-Meier method. We identified predictors of app discontinuation using Cox proportional hazards regression analysis. We quantified data completeness for both early dropouts and participants who remained engaged for longer.
    Results: Time-to-discontinuation was shortest in the year-long observational study and longest in the clinical trial. After 3 months in the study, most participants still completed surveys and audio recordings: 77% (17/22) in study 1, 59% (29/49) in study 2, and 96% (22/23) in study 3. After 3 months, passively collected location data were collected for 95% (21/22), 86% (42/49), and 100% (23/23) of the participants. The Cox regression did not provide evidence that demographic characteristics or disease severity at baseline were associated with attrition, although it was somewhat underpowered. The mean data completeness was the highest for passively collected location data. For most participants, data completeness declined over time; mean data completeness was typically lower in the month before participants dropped out. Moreover, data completeness was lower for people who dropped out in the first study month (very few data points) compared with participants who adhered long term (data completeness fluctuating around 75%).
    Conclusions: These three studies successfully collected smartphone data longitudinally from a neurodegenerative population. Despite patients' progressive physical and cognitive decline, time-to-discontinuation was higher than in typical smartphone studies. Our study provides an important benchmark for participant engagement in a neurodegenerative population. To increase data completeness, collecting passive data (such as location data) and identifying participants who are likely to adhere during the initial phase of a study can be useful.
    Trial registration: ClinicalTrials.gov NCT03168711; https://clinicaltrials.gov/ct2/show/NCT03168711.
    MeSH term(s) Activities of Daily Living ; Humans ; Mobile Applications ; Smartphone ; Surveys and Questionnaires ; Time Factors
    Language English
    Publishing date 2022-02-04
    Publishing country Canada
    Document type Journal Article ; Observational Study ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2719220-9
    ISSN 2291-5222 ; 2291-5222
    ISSN (online) 2291-5222
    ISSN 2291-5222
    DOI 10.2196/31877
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Patient reported outcomes in ALS: characteristics of the self-entry ALS Functional Rating Scale-revised and the Activities-specific Balance Confidence Scale.

    Chew, Sheena / Burke, Katherine M / Collins, Ella / Church, Reagan / Paganoni, Sabrina / Nicholson, Katharine / Babu, Suma / Scalia, Jennifer B / De Marchi, Fabiola / Ellrodt, Amy L / Moura, Lidia M V R / Chan, James / Berry, James D

    Amyotrophic lateral sclerosis & frontotemporal degeneration

    2021  Volume 22, Issue 7-8, Page(s) 467–477

    Abstract: Objective: ...

    Abstract Objective:
    MeSH term(s) Ambulatory Care Facilities ; Amyotrophic Lateral Sclerosis/diagnosis ; Disease Progression ; Humans ; Patient Reported Outcome Measures ; Self Report
    Language English
    Publishing date 2021-03-26
    Publishing country England
    Document type Journal Article
    ZDB-ID 2705049-X
    ISSN 2167-9223 ; 2167-8421
    ISSN (online) 2167-9223
    ISSN 2167-8421
    DOI 10.1080/21678421.2021.1900259
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Smartphone data during the COVID-19 pandemic can quantify behavioral changes in people with ALS.

    Beukenhorst, Anna L / Collins, Ella / Burke, Katherine M / Rahman, Syed Minhajur / Clapp, Margaret / Konanki, Sai Charan / Paganoni, Sabrina / Miller, Timothy M / Chan, James / Onnela, Jukka-Pekka / Berry, James D

    Muscle & nerve

    2020  Volume 63, Issue 2, Page(s) 258–262

    Abstract: Introduction: Passive data from smartphone sensors may be useful for health-care research. Our aim was to use the coronavirus disease-2019 (COVID-19) pandemic as a positive control to assess the ability to quantify behavioral changes in people with ... ...

    Abstract Introduction: Passive data from smartphone sensors may be useful for health-care research. Our aim was to use the coronavirus disease-2019 (COVID-19) pandemic as a positive control to assess the ability to quantify behavioral changes in people with amyotrophic lateral sclerosis (ALS) from smartphone data.
    Methods: Eight participants used the Beiwe smartphone application, which passively measured their location during the COVID-19 outbreak. We used an interrupted time series to quantify the effect of the US state of emergency declaration on daily home time and daily distance traveled.
    Results: After the state of emergency declaration, median daily home time increased from 19.4 (interquartile range [IQR], 15.4-22.0) hours to 23.7 (IQR, 22.2-24.0) hours and median distance traveled decreased from 42 (IQR, 13-83) km to 3.7 (IQR, 1.5-10.3) km. The participant with the lowest functional ability changed behavior earlier. This participant stayed at home more and traveled less than the participant with highest functional ability, both before and after the state of emergency.
    Discussion: We provide evidence that smartphone-based digital phenotyping can quantify the behavior of people with ALS. Although participants spent large amounts of time at home at baseline, the COVID-19 state of emergency declaration reduced their mobility further. Given participants' high level of daily home time, it is possible that their exposure to COVID-19 could be less than that of the general population.
    MeSH term(s) Aged ; Amyotrophic Lateral Sclerosis ; Behavior ; COVID-19 ; Data Collection ; Female ; Geographic Information Systems ; Humans ; Interrupted Time Series Analysis ; Male ; Middle Aged ; Mobile Applications ; SARS-CoV-2 ; Smartphone ; Time Factors ; Travel ; United States
    Keywords covid19
    Language English
    Publishing date 2020-11-28
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 438353-9
    ISSN 1097-4598 ; 0148-639X
    ISSN (online) 1097-4598
    ISSN 0148-639X
    DOI 10.1002/mus.27110
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Expanded access protocol (EAP) program for access to investigational products for amyotrophic lateral sclerosis (ALS).

    Yerton, Megan / Winter, Allison / Gelevski, Dario / Addy, Grace / Kostov, Anthony / Lieberman, Cassandra / Weber, Harli / Doyle, Michael / Kane, Geli / Cohen, Caroline / Parikh, Neil / Burke, Katherine M / Rohrer, Margot / Stirrat, Taylor / Bruno, Margaret / Hochman, Alison / Luppino, Sarah / Scalia, Jennifer / D'Agostino, Derek /
    Sinani, Ervin / Yu, Hong / Drake, Kristin / Hagar, Jennifer / Sherman, Alexander V / Babu, Suma / Berry, James D / Cudkowicz, Merit E / Paganoni, Sabrina

    Muscle & nerve

    2023  Volume 67, Issue 6, Page(s) 456–463

    Abstract: Introduction/aims: Expanded access protocols (EAPs) are a Food and Drug Administration (FDA)-regulated pathway for granting access to investigational products (IPs) to individuals with serious diseases who are ineligible for clinical trials. There is ... ...

    Abstract Introduction/aims: Expanded access protocols (EAPs) are a Food and Drug Administration (FDA)-regulated pathway for granting access to investigational products (IPs) to individuals with serious diseases who are ineligible for clinical trials. There is limited information about the use of EAPs in amyotrophic lateral sclerosis (ALS); the aim of this report is to share the design, operational features, and costs of an EAP program for ALS.
    Methods: The program was launched in 2018 at a single center. In alignment with FDA guidance, protocols were designed as individual (single participant) or intermediate size. Inclusion criteria were broad (e.g., no restrictions due to long disease duration or low vital capacity). Safety information was collected in all EAPs. Selected biomarkers were collected in nine of the EAPs.
    Results: From July 2018 through February 2022, 17 EAPs were submitted for FDA and institutional review board (IRB) approval. The mean time from submission to approval from the FDA and IRB were 24 days and 37 days, respectively. A total of 164 participants were enrolled and, of these, 77 participants were still receiving IP as of February 2022. The mean duration of participation in an EAP was 12.6 mo. No drug-related serious adverse events were reported from any of the EAPs. Average site cost was $613.47 per participant per month, not including IP costs.
    Conclusion: EAPs provide a framework through which access to IP can be safely provided to people with ALS who do not qualify for clinical trials. Site resources are needed to launch and maintain these programs.
    MeSH term(s) United States ; Humans ; Amyotrophic Lateral Sclerosis/drug therapy ; Time Factors ; United States Food and Drug Administration
    Language English
    Publishing date 2023-04-05
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 438353-9
    ISSN 1097-4598 ; 0148-639X
    ISSN (online) 1097-4598
    ISSN 0148-639X
    DOI 10.1002/mus.27819
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: An expanded access protocol of RT001 in amyotrophic lateral sclerosis-Initial experience with a lipid peroxidation inhibitor.

    Yerton, Megan / Winter, Allison / Kostov, Anthony / Lieberman, Cassandra / Gelevski, Dario / Weber, Harli / Doyle, Michael / Kane, Geli / Parikh, Neil / Burke, Katherine M / Rohrer, Margot / Stirrat, Taylor / Bruno, Margaret / Hochman, Alison / Luppino, Sarah / Scalia, Jennifer / Skoniecki, Debra / D'Agostino, Derek / Sinani, Ervin /
    Yu, Hong / Sherman, Alexander V / Babu, Suma / Berry, James D / Midei, Mark G / Milner, Peter G / Cudkowicz, Merit E / Paganoni, Sabrina

    Muscle & nerve

    2022  Volume 66, Issue 4, Page(s) 421–425

    Abstract: Introduction/aims: Lipid peroxidation is thought to play a biologically important role in motor neuron death in amyotrophic lateral sclerosis (ALS). 11,11 Di-deuterated linoleic ethyl ester (RT001) prevents lipid peroxidation in cellular and ... ...

    Abstract Introduction/aims: Lipid peroxidation is thought to play a biologically important role in motor neuron death in amyotrophic lateral sclerosis (ALS). 11,11 Di-deuterated linoleic ethyl ester (RT001) prevents lipid peroxidation in cellular and mitochondrial membranes. Herein we report on the use of RT001 under expanded access (EA).
    Methods: We provided RT001 to patients with ALS via EA at a single site. The starting dose was 2.88 g/day, which was increased to to 8.64 g/day as tolerated. Participants were not eligible for alternative clinical trials. Participants were followed for adverse events and pharmacokinetic (PK) parameters were measured approximately 3 months after RT001 initiation.
    Results: Sixteen participants received RT001 (5.6 ± 1.6 g/day; dose range, 1.92 to 8.64 g/day) for a mean period of 10.8 ± 7.1 months. After 3 months of treatment, PK studies showed that RT001 was absorbed, metabolized, and incorporated into red blood cell membranes at concentrations expected to be therapeutic based on in vitro models. The most common adverse events were gastrointestinal, including diarrhea, which occurred in 25% of the participants, and were considered possibly related to RT001. One participant (6%) discontinued due to an adverse event. Ten serious adverse events occurred: these events were recognized complications of ALS and none were attributed to treatment with RT001.
    Discussion: RT001 was administered safely to a small group of people living with ALS in the context of an EA protocol. Currently, there is an ongoing randomized, double-blind, controlled study of RT001 in ALS.
    MeSH term(s) Amyotrophic Lateral Sclerosis/complications ; Esters/therapeutic use ; Fatty Acids ; Humans ; Linoleic Acids/therapeutic use ; Randomized Controlled Trials as Topic
    Chemical Substances Esters ; Fatty Acids ; Linoleic Acids ; RT001 ; lipid peroxidation inhibitor
    Language English
    Publishing date 2022-07-29
    Publishing country United States
    Document type Clinical Trial Protocol ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 438353-9
    ISSN 1097-4598 ; 0148-639X
    ISSN (online) 1097-4598
    ISSN 0148-639X
    DOI 10.1002/mus.27672
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top